| NCT00791713 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2006-03 | PHASE1 |
| NCT00518323 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2007-08 | PHASE3 |
| NCT00796432 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2003-03 | PHASE1 |
| NCT00083668 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2004-04 | PHASE3 |
| NCT01010776 | Janssen-Cilag Farmaceutica Ltda. | Schizophrenia | 2008-02 | PHASE4 |
| NCT02600741 | Janssen Scientific Affairs, LLC | Schizophrenia | 2015-07-24 | |
| NCT00790777 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2007-03 | PHASE1 |
| NCT01527305 | Janssen Research & Development, LLC | Schizophrenia | 2012-06-22 | PHASE4 |
| NCT01050478 | Janssen Cilag N.V.+S.A. | Psychomotor Agitation|Acute Disease | 2010-03 | PHASE4 |
| NCT01498770 | Organon and Co | Bipolar Disorder | 2013-04-01 | |
| NCT02462473 | Janssen Research & Development, LLC | Schizophrenia|Schizoaffective Disorder | 2015-05 | PHASE2 |
| NCT00758030 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2004-03 | PHASE1 |
| NCT00752427 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2004-06 | PHASE3 |
| NCT02146547 | UMC Utrecht | Schizophrenia | 2015-02 | PHASE4 |
| NCT01795547 | H. Lundbeck A+S|Otsuka Pharmaceutical Co., Ltd. | Schizophrenia | 2013-02 | PHASE3 |
| NCT00796276 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2004-05 | PHASE1 |
| NCT00309699 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Bipolar Disorder|Mood Disorders | 2006-04 | PHASE3 |
| NCT00784238 | Janssen Korea, Ltd., Korea | Schizophrenia | 2008-04 | PHASE4 |
| NCT01157351 | Janssen Scientific Affairs, LLC | Schizophrenia | 2010-05 | PHASE4 |
| NCT00111189 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Janssen-Cilag International NV | Schizophrenia | 2005-02 | PHASE3 |
| NCT00488891 | Ortho-McNeil Janssen Scientific Affairs, LLC | Schizophrenia | 2007-04 | |
| NCT00791622 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia|Schizoaffective Disorder | 2006-01 | PHASE1 |
| NCT00791167 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2006-06 | PHASE1 |
| NCT01724359 | Janssen-Cilag, S.A. | Schizophrenia | 2008-02 | PHASE4 |
| NCT00937261 | University of California, Irvine|Janssen, LP | Schizophrenia | 2009-07 | PHASE4 |
| NCT01662310 | Janssen Research & Development, LLC | Schizophrenia | 2011-06 | PHASE3 |
| NCT03019887 | Juntendo University | Schizophrenia Relapse | 2011-04 | NA |
| NCT01134731 | University of Alabama at Birmingham|American Foundation for Suicide Prevention|Ortho-McNeil Janssen Scientific Affairs, LLC | Major Depressive Disorder|Suicidal Ideation | 2010-05 | PHASE4 |
| NCT00650793 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2004-03 | PHASE3 |
| NCT01561898 | Janssen Pharmaceutical K.K. | Schizophrenia | 2006-06 | PHASE3 |
| NCT04922593 | Luye Pharma Group Ltd. | Schizophrenia|Psychotic Disorders|Mood Disorders|Schizophrenia Spectrum|Mental Disorders|Antipsychotic Agents|Tranquilizing Agents|Central Nervous System Depressants|Physiological Effects of Drugs|Psychotropic Drugs|Neurotransmitter Agents|Molecular Mechanisms of Pharmacological Action | 2021-01-13 | PHASE1 |
| NCT04754750 | Calo Psychiatric Center | Schizophrenics | 2015-01 | PHASE1|PHASE2 |
| NCT02918825 | Beijing HuiLongGuan Hospital | Schizophrenia | 2016-09-01 | NA |
| NCT00806234 | Johns Hopkins University|National Institute of Mental Health (NIMH)|University of Maryland|University of North Carolina, Chapel Hill|The Zucker Hillside Hospital | Psychotic Disorders | 2009-01 | PHASE4 |
| NCT00761579 | Janssen Korea, Ltd., Korea | Schizophrenia | 2008-04 | PHASE4 |
| NCT01607762 | Janssen Research & Development, LLC | Healthy | 2012-02 | PHASE1 |
| NCT02433717 | National Taiwan University Hospital | Schizophrenia|Schizoaffective Disorder | 2015-04 | PHASE4 |
| NCT02374567 | Hannover Medical School | Dementia|Depression|Schizophrenia|Psychosomatic Disorders|Anxiety Disorders | 2015-01 | PHASE3 |
| NCT00299715 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Bipolar Disorder|Mood Disorders | 2006-02 | PHASE3 |
| NCT03485417 | The University of Hong Kong|Queen Mary Hospital, Hong Kong|North District Hospital | Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis)|Schizophrenia and Related Disorders|Stimulant Dependence|Stimulant Abuse|Pharmacotherapy | 2019-06-01 | PHASE2|PHASE3 |
| NCT01662648 | Janssen Pharmaceutica | Schizophrenia | 2007-06 | PHASE3 |
| NCT00077714 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2004-01 | PHASE3 |
| NCT00791401 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia|Renal Impairment | 2004-04 | PHASE1 |
| NCT00632229 | University of South Florida|Indiana University|Ortho-McNeil Janssen Scientific Affairs, LLC | Obsessive-Compulsive Disorder | 2007-10 | PHASE2 |
| NCT01825928 | Wei Hao | Methamphetamine Dependence | 2013-02 | NA |
| NCT02075528 | Taipei City Hospital|Johnson & Johnson Taiwan Ltd|Taipei Institute of Pathology | Schizophrenia|Schizoaffective Disorder | 2009-07 | PHASE4 |
| NCT00535145 | Ortho-McNeil Janssen Scientific Affairs, LLC | Schizophrenia|Schizoaffective Disorder|Psychotic Disorders | 2007-10 | PHASE4 |
| NCT00105326 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia|Insomnia | 2005-02 | PHASE2 |
| NCT00946985 | Ortho-McNeil Janssen Scientific Affairs, LLC | Schizophrenia | 2009-06 | PHASE4 |
| NCT00697658 | Janssen-Cilag B.V. | Schizophrenia | 2008-03 | |
| NCT01362426 | Janssen-Cilag Pty Ltd | Schizophrenia | 2011-03 | |
| NCT01448720 | Janssen-Cilag Farmaceutica Ltda. | Schizophrenia | 2011-09 | PHASE3 |
| NCT00210717 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2005-02 | PHASE3 |
| NCT01682161 | Janssen Korea, Ltd., Korea | Schizophrenia | 2012-01 | PHASE4 |
| NCT00796835 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2004-07 | PHASE1 |
| NCT00566631 | Janssen-Cilag International NV | Schizophrenia | 2007-07 | PHASE3 |
| NCT01211704 | University of Miami|Ortho-McNeil, Inc. | Bipolar Disorder | 2010-10 | PHASE4 |
| NCT00791349 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia|Schizoaffective Disorder | 2005-02 | PHASE1 |
| NCT00524043 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2007-09 | PHASE4 |
| NCT02893371 | University of New Mexico|Patient-Centered Outcomes Research Institute|Montana State University|National Alliance on Mental Illness Montana|CGStat LLC|Risk Benefit Statistics LLC|National Alliance on Mental Illness New Mexico|National Alliance on Mental Illness Westside Los Angeles | Bipolar Disorder | 2016-09 | |
| NCT01606254 | Janssen Pharmaceutical K.K. | Schizophrenia | 2007-01 | PHASE2 |
| NCT01559272 | Janssen Research & Development, LLC | Schizophrenia | 2008-02-21 | PHASE1 |
| NCT00101634 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2004-12 | PHASE3 |
| NCT00668837 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2004-02 | PHASE3 |
| NCT01451736 | University of California, Los Angeles|National Institute of Mental Health (NIMH)|Janssen Scientific Affairs, LLC | Schizophrenia (Recent-onset) | 2011-10 | PHASE4 |
| NCT00838669 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2005-08 | PHASE1 |
| NCT00119756 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2005-06 | PHASE3 |
| NCT01110317 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2005-07 | PHASE1 |
| NCT00086320 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2004-03 | PHASE3 |
| NCT00210548 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2005-04 | PHASE3 |
| NCT01399450 | Seoul National University Hospital|Johnson & Johnson | Schizophrenia | 2011-08 | PHASE4 |
| NCT01947803 | Xian-Janssen Pharmaceutical Ltd. | Schizophrenia | 2013-09 | PHASE4 |
| NCT01387542 | Janssen-Cilag Ltd.,Thailand | Schizophrenia | 2009-08 | PHASE4 |
| NCT03425552 | Pharmathen S.A. | Schizophrenia | 2018-03-11 | PHASE1|PHASE2 |
| NCT03080194 | Maosheng Fang | Schizophrenia | 2017-04 | PHASE4 |
| NCT00350467 | Xian-Janssen Pharmaceutical Ltd. | Acute Schizophrenia | 2006-06 | PHASE3 |
| NCT00761189 | Janssen Korea, Ltd., Korea | Schizophrenia | 2008-02 | PHASE4 |
| NCT01150448 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2007-09 | PHASE1 |
| NCT00796081 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorders | 2006-01 | PHASE1 |
| NCT00412373 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Janssen, LP | Schizoaffective Disorder|Psychotic Disorder | 2006-12 | PHASE3 |
| NCT00791193 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2007-03 | PHASE1 |
| NCT00590577 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2007-03 | PHASE3 |
| NCT01009047 | Janssen Research & Development, LLC | Schizophrenia | 2009-12 | PHASE3 |
| NCT01281527 | Janssen-Cilag International NV | Schizophrenia | 2010-11 | PHASE3 |
| NCT01584466 | University of Maryland, Baltimore | Schizophrenia | 2014-01 | NA |
| NCT00757705 | Johnson & Johnson Taiwan Ltd | Schizophrenia | 2008-03 | PHASE4 |
| NCT01136772 | New York State Psychiatric Institute|National Institute of Mental Health (NIMH)|Duke University|University of North Carolina, Chapel Hill | Schizophrenia|Schizoaffective Disorder | 2011-03 | PHASE4 |
| NCT00535132 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2007-10 | PHASE4 |
| NCT01942382 | Janssen Pharmaceutical K.K. | Schizophrenia | 2009-04 | PHASE1 |
| NCT00915512 | Janssen-Cilag Turkey | Schizophrenia | 2009-05 | PHASE4 |
| NCT03666715 | Janssen-Cilag Farmaceutica Ltda. | Schizophrenia | 2018-08-07 | |
| NCT01577186 | Johnson & Johnson Taiwan Ltd | Schizophrenia | 2008-07 | PHASE4 |
| NCT01822730 | Wei Hao | Methamphetamine Dependence | 2013-02 | PHASE4 |
| NCT01860781 | Seoul National University Hospital | Schizophrenia | 2011-08 | PHASE4 |
| NCT00490971 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Bipolar Disorder | 2006-05 | PHASE3 |
| NCT00085748 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2004-08 | PHASE3 |
| NCT00934635 | Janssen-Cilag G.m.b.H | Schizophrenia | 2009-09 | PHASE4 |
| NCT00589914 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2007-03 | PHASE3 |
| NCT01742390 | Si Tianmei | Sexual Dysfunction|Hyperprolactinemia | 2013-02 | PHASE4 |
| NCT01081769 | Janssen-Cilag International NV | Schizophrenia | 2010-02 | PHASE3 |
| NCT04572685 | Luye Pharma Group Ltd.|Alliance for Clinical Trials in Oncology|Evolution Research Group | Schizophrenia Patients | 2020-01-22 | PHASE1 |
| NCT00645307 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2004-05 | PHASE3 |
| NCT00604279 | Xian-Janssen Pharmaceutical Ltd. | Schizophrenia | 2008-01 | PHASE3 |
| NCT02713282 | Janssen-Cilag Ltd. | Schizophrenia | 2016-04-28 | PHASE3 |
| NCT03557931 | Astellas Pharma Global Development, Inc. | Schizophrenia | 2018-07-13 | PHASE2 |
| NCT00488319 | Janssen Research & Development, LLC | Schizophrenia|Schizophrenic Disorders|Psychotic Disorders|Dementia Praecox | 2007-06 | PHASE3 |
| NCT01362439 | Janssen-Cilag S.p.A. | Schizophrenia | 2009-01 | PHASE4 |
| NCT03345979 | Alkermes, Inc. | Schizophrenia | 2017-11-15 | PHASE3 |
| NCT00645099 | Janssen-Cilag International NV | Schizophrenia | 2007-10 | PHASE3 |
| NCT01685931 | Xian-Janssen Pharmaceutical Ltd. | Schizophrenia | 2012-11 | PHASE4 |
| NCT01193153 | Janssen Scientific Affairs, LLC | Schizoaffective Disorder | 2010-09 | PHASE3 |
| NCT07493551 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Schizophrenia | 2024-10-09 | NA |
| NCT04478838 | Centre for Addiction and Mental Health | Schizophrenia and Related Disorders|Drug Administration Schedule|Drug Therapy|Antipsychotic Agents | 2022-06-06 | PHASE4 |
| NCT03809325 | Janssen-Cilag International NV | Schizophrenia | 2018-11-21 | |
| NCT01181960 | Janssen Scientific Affairs, LLC | Schizophrenia|Bipolar Disorder | 2010-08 | |
| NCT01193166 | Ortho-McNeil Janssen Scientific Affairs, LLC | Schizophrenia | 2010-08 | PHASE4 |
| NCT00257023 | Janssen Pharmaceutical K.K. | Schizophrenia | 2005-02 | PHASE2 |
| NCT00592358 | Massachusetts General Hospital | Pediatric Bipolar Disorder | 2007-11 | PHASE4 |
| NCT03390712 | Réseau de Santé Vitalité Health Network|Janssen Inc. | Schizophrenia Spectrum and Other Psychotic Disorders | 2018-01-02 | |
| NCT00396565 | Janssen Pharmaceutical K.K. | Schizophrenia | 2006-07 | PHASE3 |
| NCT01060228 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia|Epilepsy | 2009-01 | PHASE1 |
| NCT01051531 | Janssen Research & Development, LLC | Schizophrenia | 2010-04-22 | PHASE3 |
| NCT00334126 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Janssen, LP | Schizophrenia | 2006-04 | PHASE3 |
| NCT00210769 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2004-01 | PHASE3 |
| NCT07075237 | Jiangsu Province Nanjing Brain Hospital | Schizophrenia | 2025-10 | PHASE4 |
| NCT06060886 | Consorcio Centro de Investigación Biomédica en Red (CIBER)|Instituto de Salud Carlos III | Schizophrenia|Treatment-resistant Schizophrenia|Side Effect|Lipid Metabolism Disorders|Diabetes|NAFLD|Psychosis | 2023-11-01 | PHASE4 |
| NCT02307396 | Technical University of Munich | Schizophrenia|Schizophrenia and Disorders With Psychotic Features|Schizoaffective Disorders | 2015-02-01 | PHASE4 |
| NCT01299389 | Janssen Pharmaceutical K.K. | Schizophrenia | 2010-10 | PHASE3 |
| NCT02087579 | Janssen Research & Development, LLC | Psychotic Disorders|Schizophrenia|Bipolar Disorder|Depressive Disorder | 2014-02 | PHASE1 |
| NCT07047651 | Dr. Stavroula Rakitzi | Treatment Resistant Schizophrenia|Treatment Resistant Bipolar Disorder | 2025-06-04 | PHASE4 |
| NCT00549562 | Indiana University|Ortho-McNeil Janssen Scientific Affairs, LLC | Autism | 2007-11 | PHASE3 |
| NCT00309686 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Affective Psychosis, Bipolar|Bipolar Disorder|Mania | 2006-04 | PHASE3 |
| NCT04076371 | Beijing HuiLongGuan Hospital | Schizophrenia | 2012-01 | NA |
| NCT00460512 | Janssen-Cilag International NV | Schizophrenia | 2007-04-25 | PHASE3 |
| NCT01606228 | Janssen Pharmaceutica | Schizophrenia | 2007-12 | PHASE3 |
| NCT07153835 | Sher-E-Bangla Medical College|ACI Pharmaceuticals|US-Bangla Medical College Hospital|Dr. M M Jalal Uddin|Dr.Ahsan Aziz Sarkar | Schizophrenia | 2025-09-01 | PHASE4 |
| NCT04064476 | Huazhong University of Science and Technology | Schizophrenia | 2019-08-18 | |
| NCT00892320 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2004-03 | PHASE1 |
| NCT01258920 | Janssen Pharmaceutical K.K. | Schizophrenia | 2010-10 | PHASE3 |
| NCT00791232 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2003-03 | PHASE1 |
| NCT03730857 | Calo Psychiatric Center | Schizophrenia | 2008-01 | PHASE1 |
| NCT00892125 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia|Bipolar Disorder | 2006-09 | PHASE1 |
| NCT00073320 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2003-08 | PHASE3 |
| NCT00827840 | Chonnam National University Hospital|Janssen Korea, Ltd., Korea|Ministry of Health, Republic of Korea | Schizophrenia | 2008-11 | PHASE4 |
| NCT01157585 | Chonbuk National University Hospital|Janssen Korea, Ltd., Korea | First Episode Psychosis | 2010-02 | PHASE4 |
| NCT07268430 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Schizophrenia | 2023-12-18 | NA |
| NCT00330863 | Northwell Health|National Institute of Mental Health (NIMH) | Schizophrenia|Schizoaffective Disorder | 2006-05 | PHASE4 |
| NCT00766064 | Yale University | Posttraumatic Stress Disorder | 2008-09 | PHASE4 |
| NCT01577160 | Johnson & Johnson Taiwan Ltd | Schizophrenia | 2008-05 | PHASE4 |
| NCT00796185 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia|Schizoaffective Disorder | 2003-08 | PHASE1 |
| NCT00892489 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2004-07 | PHASE1 |
| NCT00761605 | Janssen Korea, Ltd., Korea | Schizophrenia | 2008-04 | PHASE4 |
| NCT02431702 | Janssen Scientific Affairs, LLC | Schizophrenia|Psychotic Disorders | 2015-07-08 | PHASE3 |
| NCT01541371 | Xian-Janssen Pharmaceutical Ltd. | Schizophrenia | 2008-07 | PHASE3 |
| NCT03713658 | Janssen Research & Development, LLC | Schizophrenia | 2018-10-18 | PHASE4 |
| NCT00397033 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Janssen, LP | Schizoaffective Disorder|Psychotic Disorder | 2006-11 | PHASE3 |
| NCT00473434 | Janssen-Cilag Pty Ltd | Schizophrenia | 2007-04 | PHASE3 |
| NCT02634463 | Janssen Research & Development, LLC | Immunoassay|Antipsychotic | 2015-11-09 | PHASE1 |
| NCT01284959 | Chonbuk National University Hospital|AstraZeneca|Janssen Korea, Ltd., Korea|Korea Otsuka Pharmaceutical Co., Ltd.|Sanofi-Synthelabo | Schizophrenia | 2010-06 | PHASE4 |
| NCT00791284 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia|Hepatic Impairment | 2004-08 | PHASE1 |
| NCT00796640 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2003-09 | PHASE1 |
| NCT00892541 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2004-10 | PHASE1 |
| NCT01279213 | Universidad Nacional de Rosario | Schizophrenia|Schizophrenic Disorders|Psychotic Disorder | 2009-01 | PHASE4 |
| NCT00078039 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2004-03 | PHASE3 |